[HTML][HTML] Biomaterial vaccines capturing pathogen-associated molecular patterns protect against bacterial infections and septic shock
…, KR Lightbown, FR Urena, CD Yeager… - Nature Biomedical …, 2022 - nature.com
Most bacterial vaccines work for a subset of bacterial strains or require the modification of the
antigen or isolation of the pathogen before vaccine development. Here we report injectable …
antigen or isolation of the pathogen before vaccine development. Here we report injectable …
Scaffold vaccines for generating robust and tunable antibody responses
…, AG Stafford, JC Weaver, CD Yeager… - Advanced Functional …, 2022 - Wiley Online Library
Traditional bolus vaccines often fail to sustain robust adaptive immune responses, typically
requiring multiple booster shots for optimal efficacy. Additionally, these provide few …
requiring multiple booster shots for optimal efficacy. Additionally, these provide few …
Modular biomaterials vaccine technology protects against multiple pathogens and septic shock
Broad spectrum vaccines could provide a solution to the emergence of antibiotic resistant
microbes, pandemics and engineered biothreat agents. Here, we describe a modular vaccine (…
microbes, pandemics and engineered biothreat agents. Here, we describe a modular vaccine (…
A Modular biomaterial Scaffold‐based vaccine elicits durable adaptive immunity to subunit SARS‐CoV‐2 antigens
F Langellotto, MO Dellacherie, C Yeager… - Advanced …, 2021 - Wiley Online Library
The coronavirus disease 2019 (COVID‐19) pandemic demonstrates the importance of
generating safe and efficacious vaccines that can be rapidly deployed against emerging …
generating safe and efficacious vaccines that can be rapidly deployed against emerging …
A rapidly adaptable biomaterial vaccine for SARS-CoV-2
…, BT Seiler, J Yu, MJ Cartwright, D White, C Yeager… - bioRxiv, 2020 - biorxiv.org
The global COVID-19 pandemic motivates accelerated research to develop safe and
efficacious vaccines. To address this need, we leveraged a biomaterial vaccine technology that …
efficacious vaccines. To address this need, we leveraged a biomaterial vaccine technology that …
A rapidly adaptable biomaterial vaccine for SARS-CoV-2 (preprint)
…, BT Seiler, J Yu, MJ Cartwright, D White, C Yeager… - 2020 - pesquisa.bvsalud.org
ABSTRACTThe global COVID-19 pandemic motivates accelerated research to develop safe
and efficacious vaccines. To address this need, we leveraged a biomaterial vaccine …
and efficacious vaccines. To address this need, we leveraged a biomaterial vaccine …
Special Purpose Application Reactors: Systems Integration Decision Support
Microreactors, also known as very-Small Modular Reactors (vSMRs) or Special Purpose
Reactors (SPRs), are being considered for use in unique applications where other methods of …
Reactors (SPRs), are being considered for use in unique applications where other methods of …
[HTML][HTML] Characterization of paralogous uncx transcription factor encoding genes in zebrafish
…, T Kondo, F Ristoratore, LMT Canzoniero, D Duboule… - Gene, 2019 - Elsevier
The paired-type homeodomain transcription factor Uncx is involved in multiple processes of
embryogenesis in vertebrates. Reasoning that zebrafish genes uncx4.1 and uncx are …
embryogenesis in vertebrates. Reasoning that zebrafish genes uncx4.1 and uncx are …
Mesoporous Silica Rods Scaffolds for the generation of adaptive immune responses
MO Dellacherie - 2021 - search.proquest.com
… Fernanda Langelloto and Chyenne Yeager for the incredible work they did on the MSR
SARS-CoV-2 vaccine, a lot of which was done while most of the country was isolating at home in …
SARS-CoV-2 vaccine, a lot of which was done while most of the country was isolating at home in …
Materials to enable and enhance T-cell immunotherapies
K Zhang - 2021 - search.proquest.com
Immunotherapies involving engineered T cells have shown remarkable clinical outcomes
for the treatment of cancer, particularly hematological malignancies, such as leukemia and …
for the treatment of cancer, particularly hematological malignancies, such as leukemia and …